M&A / Deals BMS, Hengrui build 13-asset pipeline in $15B+ onco-immune deal BioSpaceOf the 13 programs that the companies will advance, four will come from Hengrui Pharma and four from Bristol Myers Squibb.OncologyRead full story pharminent May 12, 2026 (Last updated: May 12, 2026) BioSpace Of the 13 programs that the companies will advance, four will come from Hengrui Pharma and four from Bristol Myers Squibb. Oncology Read full story Post navigation Previous: Bristol Myers, Hengrui join forces in drugmaking alliance worth up to $15.2 billionNext: Arvinas, Pfizer find new partner for ‘Protac’ breast cancer drug Related Stories M&A / Deals BioMarin spends up to $490m for Alesta’s bone disease candidate pharminent August 19, 2026 M&A / Deals J&J hands lymphoma bispecific CAR T back to AbelZeta pharminent August 17, 2026 M&A / Deals Novo Nordisk and AWS form AI partnership to speed drug discovery pharminent August 17, 2026
